The current study aims to determine the prevalence of antibodies to Rubella in pregnant and non-pregnant women. The study uses two methods: traditional enzyme-linked immunosorbent assay (ELISA) and rapid immunochromatography (RIC). The study involved 240 women ranging in age from 16 to 45 years. Among the 240 participants, 125 were pregnant. All participants provided informed written consent to participate. The present study was approved by the Ethics Committee of Shri BM Patil Medical College, Pune, India.
The prevalence of rubella in pregnant women was determined using a meta-analysis of a large number of studies published in the past decade. It reported that global seronegativity was approximately 5% of women of childbearing age. It is important to note that WHO sets the threshold for rubella susceptibility at 5% for women of childbearing age. A recent review of the literature found that there were more than 10 reports of the virus in Congo. The current study is a landmark work that contributes to the knowledge about the disease and helps health care providers design a more effective and timely surveillance program.
A previous study of pregnant women in Namibia showed a seroprevalence rate of about 85%. The seroprevalence was highest in rural women, while rates were lower in urban women. However, CDC-acquired results were significantly higher in pregnant women. The findings suggest that the differences are related to the nature of the infection, the type of test performed, and the size of the sample.
Despite these findings, the importance of testing for antirubella IgG is a matter of debate. In the last few years, the incidence of rubella has decreased considerably in developing countries. Some studies report that 80% of pregnant women are infected with the disease. Other recent studies have shown that anti-rubella IgG seroprevalence is higher among urban women, and some pregnant women show higher rates than in rural women. In addition, the increased prevalence of Rubella seroprevalence is correlated with socioeconomic status.
To understand the global burden of rubella, more accurate information about laboratory and epidemiological data is needed. The study of Nepalese women found a 90% seroprevalence rate for IgG antibodies against rubella. Similarly, Tanzanian children had a 5% seroprevalence rate. In order to accurately assess the prevalence of rubella, a wider range of tests should be used.
There are several studies on the prevalence of rubella in the world. The first study in Nigeria found a seroprevalence of over ninety percent among pregnant and non-pregnant women. The second study, a study in Turkey, evaluated schoolgirls in the city of Istanbul and found a similar prevalence in pregnant and non-pregnant populations. In the USA, the prevalence was 5%.